Bone metabolism during long-term treatment with imatinib

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1783-1785

  O'Sullivan, Susannah ^a   Horne, Anne ^a   Wattie, Diana ^a   Porteous, Fran ^a   Gamble, Greg ^a   Browett, Peter ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; IMATINIB; PARATHYROID HORMONE; PHOSPHATE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FEMALE; FEMUR; FOLLOW UP; HUMAN; LETTER; LEUKEMIA REMISSION; LUMBAR SPINE; MALE; PHOSPHATE URINE LEVEL; PHOSPHATURIA; POST HOC ANALYSIS; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; STUDENT T TEST; TREATMENT DURATION; URINALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84880324151     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.760734     Document Type: Letter

References (24)

1. Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98: 2483-2487
2. Deininger M W, O B rien S G, Ford J M, et a l. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003 ; 21 : 1637-1647
3. O Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. JBone Miner Res 2007; 22: 1679-1689
4. Tibullo D, Giallongo C, La Cava P, et al. effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009 ; 37 : 461-468
5. El Hajj Dib I, Gallet M, Mentaverri R, et al. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 2006; 551: 27-33
6. Vandyke K, Fitter S, Dewar A L, et a l. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010 ; 115 : 766-774
7. O'Sullivan S, Naot D, Callon K, et al. Imatinib mesylate does not increase bone volume in vivo. Calcif Tissue Int 2011; 88: 16-22
8. Grey A, O Sullivan S, Reid IR, et al. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. NEngl J Med 2006 ; 355 : 2494-2495
9. O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009; 94: 1131-1136
10. Jö nsson S, Standal T, Olsson B, et al. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol 2012 ; 87 : 550-552
11. Jö nsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008; 93: 1101-1103
12. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. NEngl J Med 2006 ; 354 : 2006-2013
13. O S ullivan S, Lin J -M, Watson M, et a l. The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 2011 ; 49 : 281-289
14. Baldazzi V, Tassi R, Lapini A, et al. Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis. Cancer 2012 ; 118 : 3165-3172
15. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007 ; 109 : 5143-5150
16. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012; 119: 3403-3412
17. McClung M R, Lewiecki E M, Cohen S B, et a l. Denosumab in postmenopausal women with low bone mineral density. NEngl J Med 2006 ; 354 : 821-831
18. Reid IR. Relationships between fat and bone. Osteoporos Int 2008 ; 19 : 595-606
19. Schmid H, Jaeger B AS, Lohse J, et a l. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on longterm treatment with imatinib. Haematologica 2009 ; 94 : 1177-1179
20. Rastogi MV, Stork L, Druker B, et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer 2012 ; 59 : 840-845
21. Mariani S, Giona F, Basciani S, et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008; 372: 111-112
22. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growthat prepubertal and pubertal ages of children with chronic myeloid leukemia. JPediatr 2011 ; 159 : 676-681
23. Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012 ; 59 : 481-484
24. Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011 ; 17 : S115-S122